DCI Research

New research from Dan George, MD, & team emphasizes the importance of diversity in clinical trials after finding a particular drug combo was more successful in Black men.

A biomarker developed with digitalized pathology and AI identified which men treated with radiation for high-risk localized prostate cancer could benefit with short-term drug treatment.

The Duke University School of Medicine is proud to acknowledge faculty members selected as recipients of this year’s School of Medicine faculty awards, which includes three from DCI.

Of 27 faculty from the School of Medicine awarded distinguished professorships this year, 10 are members of Duke Cancer Institute.

Omidubicel, a new cellular therapy, expands the availability of allogeneic (donor) stem cell transplants to more patients.

DCI is among the first in the nation to offer a targeted radiopharmaceutical therapy for men with advanced prostate cancer that's progressed on other treatments.

Delayed diagnosis and treatment of sarcoma may increase risk of metastatic cancer.

Study results set the stage for use of a liquid biopsy of circulating tumor cells to help identify men who could benefit from PSMA-targeted therapy.

A DCI team led by Peter Allen, MD, chief of Surgical Oncology, finds way to help determine likelihood of pancreas cysts becoming cancerous.

Cancer patients said the COVID-19 pandemic heightened infection concerns, increased feelings of fear, and disrupted their care.

Duke Cancer Institute has named five DCI faculty to new leadership roles.

Daniel Nussbaum, MD, is one of 12 investigators to have been selected by National Cancer Institute for their Early-Stage Surgeon Scientist Program (ESSP).

Tomi Akinyemiju, PhD, DCI epidemiologist and associate director, COEE, has received Duke funds to research climate change, radon exposure & lung cancer.

A metastatic breast cancer drug, discovered in the McDonnell Lab, is now FDA-approved—the first new oral endocrine therapy in 20+ years. Another might not be so far behind.

Gerard Blobe, MD, PhD, and Micah Luftig, PhD, are co-principal investigators on an NIH grant to develop a post-baccalaureate program for students interested in biomedical or basic science.

John Strickler, MD, and team's milestone work on the clinical trial "MOUNTAINEER" has led to the first FDA-approved treatment regimen for HER2+ metastatic colorectal cancer.

In a global phase 1/2 clinical trial, sotorasib “demonstrated meaningful anticancer activity in patients with heavily pre-treated KRAS G12C–mutated advanced pancreatic cancer.”

The hybrid retreat showcased the latest gastric cancer, blood cancer, pediatric sarcoma, glioblastoma, breast cancer, and immune micro-environment research.

DCI leaders Leah Zullig, PhD, MPH, and Kevin Oeffinger, MD, developed ONE TEAM, a tool that encourages patients to manage their own health.

Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured in the media, trades, journals, at Duke and the DCI blog.

Peter Fecci, MD, PhD, is the co-editor of the new e-book — "It Takes a Village: The Expanding Multi-Disciplinary Approach to Brain Metastasis."

DCI member H. Kim Lyerly, MD, and pediatric neuro-oncologist Daniel Landi, MD, are co-leaders on the new cross-institutional project.

The Duke Med Alumni News Fall '22 Issue's cover story is "Researchers at Duke are Creating More Precise Approaches to Stopping Tumors."

As Duke celebrates more than 50 years of cancer breakthroughs, a new research program works toward a future when no one ever develops cancer.

Can a new test diagnose pancreatic cancer in the early stages?

The 2022 Web of Science citation index of Most Cited Scientists — nearly 7,000 authors worldwide — includes 30 researchers at Duke.

Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured in the media, trades, journals, at Duke and the DCI blog.

Learn how the Precision Cancer Medicine Initiative is advancing research, extending lives, and breaking down barriers to access.

The Duke BioRepository & Precision Pathology Center, a Duke School of Medicine Service Center and DCI Shared Resource turns 10.

Learn about some notable BRPC/DCI cancer research collaborations and why the partnership is core to winning big grants for cancer research.

Learn about new developments in next generation molecular sequencing tests at the DUHS Clinical Labs' Clinical Molecular Diagnostics Laboratory.

A family history of cancer and genetic variants that might be inherited appear to be important risk factors for Black men diagnosed with early-onset prostate cancer.

DCI researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire.

Researchers mapping a molecular atlas for ductal carcinoma in situ have developed a predictive model to distinguish which cases will progress.

STUDY: Non-Hispanic Black patients are less likely to receive guideline-appropriate treatment for ovarian cancer than non-Hispanic White patients.

DCI oncologists — doctors Davidson, Kamal, Moss, Secord, Menendez, and Kelley — blaze a trail, at the national level, in breast & gynecologic cancers.

Amanda Randles, PhD, will use the Pioneer Award to create AI models that estimate a person’s blood flow dynamics over time with the help of wearable devices like smart watches.

A team led by Duke biochemistry professor Bruce Donald, PhD, has developed an algorithm to predict how mutations in an enzyme will affect a drug’s efficacy.

The Radiation Research Society bestowed its highest honor — the Failla Memorial Lecture Award — on Michael B. Kastan, MD, PhD, executive director of DCI.

DCI radiation oncologist Christine Eyler, MD, PhD, was awarded an NCI Mentored Clinical Scientist Research Career Development Award for rectal cancer and chemo-radiotherapy research.

Congratulations to David Kirsch, MD, PhD, whose NCI Outstanding Investigator Award to study radiation and sarcoma biology has been renewed for another 7 years.

Zach Reitman, MD, PhD, was awarded an NCI Mentored Clinical Scientist Research CDA for research into targeted radiation therapy in pediatric brainstem tumors.

Brent Hanks, MD, PhD, and his lab team will trial a drug that targets the NLRP3 pathway, so as to unblock immunotherapy from working in melanoma patients.

Five questions for gynecologic oncologist Brittany Davidson, MD, about the best approach to patient goals and treatment expectations in terminal ovarian cancer

New nanoparticle shape can greatly enhance signals from multiple separate biomarkers at once, accurately detecting head and neck cancers without biopsies to improve global health

The Division of Gynecologic Oncology, Duke Department of OB-GYN commemorates 50 years of innovation and care.

"Just ASK," a course developed and piloted at DCI by Nadine Barrett, PhD, to help improve equity, diversity, and inclusion in cancer clinical trials, has gone national.

Trudy G. Oliver, PhD, has joined DCI from the Huntsman Cancer Institute as a Duke Science and Technology Scholar. Her research focuses on subtypes of lung cancer.

A research team led by Ann Marie Pendergast, PhD, found, in animal studies, that a leukemia drug disrupted HER2-positive breast cancer-spread to the brain.

David Darr has been named Associate Director of Administration and Senior Director for Research Strategy and Operations for DCI, effective August 15.